This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Astellas Pharma, Eisai, Daiichi Sankyo and Takeda have agreed to collaborate to reduce the environmental burden in the field of pharmaceutical packaging. As part of the collaboration, the four pharma companies plan to share knowledge on packaging technologies to reduce environmental burden. . Areas covered will include blister packs made of biomass-based plastic instead of petroleum-derived plastic, compact packaging, recycled packaging materials, and recyclable packaging materials.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Flu activity across the United States continues to decline, though it remains at high levels in most parts of the country, the Centers for Disease Control and Prevention reported Friday in its weekly influenza update for the week ending Dec. 17. The percentage of people seeking medical care for influenza-like illness dropped for the third straight week, and hospitalizations due to flu declined for the second week in a row.
Dr. Syra Madad of the NYC hospital system and an Infectious Disease Epidemiologist at Harvard's Belfer Center for Science and International Affairs responded to Dr. Anthony Fauci's, director of NIAID, statement made in late November that the U.S. is “certainly” still in the middle of a Covid-19 pandemic.
The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Last year, medical records opened up to patients. This year, they’re opening up to the nation. Before the ball drops on New Year’s Eve, electronic health care record vendors will have to provide tools to easily pull big batches of patient data from their systems. Just as information blocking rules gave individual patients the ability to access their medical records, this next round of federal rules gives a framework for sharing insights — within a health system, or with trus
The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.
SAN FRANCISCO — A prominent California medical school has apologized for conducting dozens of unethical medical experiments on at least 2,600 incarcerated men in the 1960s and 1970s, including putting pesticides and herbicides on the men’s skin and injecting it into their veins. Two dermatologists at the University of California, San Francisco — one of whom remains at the university — conducted the experiments on men at the California Medical Facility, a prison hospit
In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). They’ve laid the necessary groundwork for cross-functional visibility, collaboration, and connectivity. And in 2023, these investments will hopefully pay off. Here are seven commercial predictions from Veeva’s industry experts for the year ahead.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Congress is expected to pass a massive $1.7 trillion omnibus spending package that includes numerous provisions aimed at addressing the opioid epidemic. I have been advocating for greater access to opioid addiction treatment for more than two decades. While the spending package contains many positive opioid treatment reforms, I am deeply concerned that Congress and others without on-the-ground experience will continue pushing dangerous policies to solve the opioid epidemic in the next Congress.
Scrutiny of the lifecycle management of buffer solutions has increased recently. However, it has been one of the most overlooked yet fundamental parts of the manufacturing process for biomolecules for many years. The potential for bottlenecks within the scheduling process has a direct effect on facility productivity and a significant impact on the overall cost of manufacturing.
With his Parker Institute for Cancer Immunotherapy, Sean Parker has been building a dream team of cancer researchers. Since 2016, the Parker Institute — known as PICI for short — has poured hundreds of millions of dollars into six research centers that it’s created at some of the top academic institutions in the country and folded luminaries like the CAR-T pioneer Carl June and Nobel Prize winner Jim Allison into its network.
The FDA has given a green light to Roche’s CD20xCD3 bispecific antibody Lunsumio as a treatment for relapsed or refractory follicular lymphoma, following the lead of the European Commission which cleared the drug in June. The US regulator has approved Lunsumio (mosunetuzumab) for the same indication – patients who have previously been treated with two or more lines of systemic therapy – making it the first CD20xCD3 bispecific to be authorised for this form of non-Hodgkin lymphoma (NHL).
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Good morning, Pharmalittle family! Your loyal scribe Ed Silverman is taking today off, so he bestowed upon me, Adam Feuerstein, the great honor of delivering today’s roundup of pharma news. But first, my coffee: Intelligentsia House Blend, brewed in a Chemex. Old school. Hints of apple, citrus, and milk chocolate. Or, so they say. To me, it just tastes like a really good cup of joe on a stormy Friday morning.
The US Food and Drug Administration (FDA) has approved Gilead’s Sunlenca (lenacapavir), a capsid inhibitor for adults living with human immunodeficiency virus type 1 (HIV-1), who cannot be successfully treated with other available treatments. Sunlenca is the first of a new class of drugs called capsid inhibitors to be approved by the FDA for treating HIV-1.
Merry Christmas! The holidays are a good time to reflect and give thanks. Our entire team is always grateful and giving thanks for all our blessings. We are thankful for our clients who have been with us for many years, as well as the new partners who joined us in 2022. A successful year would be impossible without our hardworking team. We are thankful for all they do throughout the year to support our clients.
Participants who survived Hodgkin lymphoma as children showed signs of being biologically older than their peers, with a heightened risk of cognitive problems.
BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which aims to develop a multi-antigen malaria vaccine. The study will assess a set of mRNA-encoded antigens of the malaria-causing parasite, plasmodium falciparum, in order to select the best candidate to progress to further stages of the trials.
Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.
Celltrion has announced that it has finalised its submission of a biologics license application for the subcutaneous version of a biosimilar to anti-inflammatory medicine Remicade, to be submitted to the FDA. CT-P13 SC, also known as Remsima SC, is the company’s subcutaneous (SC) formulation of the infliximab biosimilar for Johnson & Johnson’s Remicade, which treats rheumatoid arthritis.
Jawad Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.
US biotech company Moderna has finalised a partnership with the UK government to produce vaccines, the main element of which is the construction of a new manufacturing centre in the UK. The aim of the partnership is to generate a ready supply of UK-produced mRNA vaccines for COVID-19 and other infectious diseases like flu and respiratory syncytial virus (RSV).
Steve Simske, PhD, discusses his research investigating how the occurrence of discrimination in biology can act as an agnostic analogy for discrimination in humans’ social environments.
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Sunlenca (lenacapavir) plus other antiretroviral(s) (ARV) to treat human immunodeficiency virus type 1 (HIV-1) infection. The treatment is indicated for adult patients who are heavily treatment-experienced (HTE) with multi-drug resistant (MDR) HIV-1 infection. This approval is backed by findings from the multicentre, double-blinded, placebo-controlled, international Phase II/III CAPELLA clinical trial of lenacap
Molnupiravir, made by Merck, Sharp and Dohme (MSD), has been found to reduce the recovery time of COVID-19 patients, however it did not decrease mortality rates or hospital admissions. The trial was conducted to see whether it followed previous studies of molnupiravir, which had looked at its effectiveness at reducing hospital admissions among patients with mild-to-moderate COVID-19.
Merck & Co’s efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China’s Kelun-Biotech that spans seven antibody-drug conjugates (ADCs) in early development. Merck is paying a relatively modest $175 million upfront to secure rights to the programmes, along with an undisclosed equity investment, but the combined value of the deal could reach an eye-watering $9.3 billion if all seven make
Merck (MSD outside North America) has signed an exclusive licence and partnership agreement with Kelun-Biotech for developing seven investigational preclinical antibody-drug conjugates (ADC) to treat cancer. As per the deal, Merck will receive exclusive international licences from Kelun-Biotech for carrying out the research, development, production and marketing of these ADC therapies.
The European Commission (EC) has granted conditional marketing authorisation for Zynlonta ® (loncastuximab tesirine), a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Zynlonta is being developed by Sobi and ADC Therapeutics. The approval follows a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use in September.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
98 
Let's personalize your content